News headlines DexCom (DXCM) is positioned as a strong long-term investment in the healthcare sector, benefiting from regulatory changes and recent upgrades by analysts. The company's continuous ...

Dexcom’s G6 (left) and G7 (right) side-by-side. [Image from Dexcom] A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose monitor ...

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo as ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

DexCom, which has underperformed its medical equipment and S&P 500 peers in a big way in 2025, could be staring at better prospects next year. Stelo is facing vast and underpenetrated prediabetes and ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...